BioSpace News Archive

Business competition illustration featuring businessman standing on stacked dollar representing financial success, salary growth, wealth inequality, and achievement

Lilly’s $25B+ M&A spree captures half of pharma’s 2026 capacity

Over the past decade, Eli Lilly has bought out more biotechs than any of the other top 12 pharmas by revenue—with 10 of those acquisitions arriving just this year.

June 10, 2026

·

1 min read

·

Annalee Armstrong

Social media networking. Network with members connected with each other. Group of people. Communication, teamwork, community, society. Abstract concept with wooden pieces on blue background.

Opinion

Local trade groups must support life sciences in these difficult times

As the industry faces policy changes and significant cuts to federal funding, local ecosystems can bolster companies through innovative resources to sustain growth and keep the U.S. at the center of biomedical innovation.

June 10, 2026

·

4 min read

·

Jennifer Hawks Bland

A brain hovers over a hand against a yellow-striped background

Alzheimer’s disease

Lilly bets up to $1B+ with AlzeCure in search for next Alzheimer’s act

The star of the licensing agreement, a small-molecule gamma-secretase modulator, will help buff Eli Lilly’s position in Alzheimer’s disease, currently headlined by its anti-amyloid antibody Kisunla.

June 10, 2026

·

2 min read

·

Tristan Manalac

Large yellow signboard on metal frame with the word IPO. Clear sky in the background. Concept of share trading on stock market, capital investment, currency exchange

IPO

Update: Parabilis raises industry-record $670M IPO

Parabilis Medicines is joining the parade of biotechs going public, with one key difference—more money.

June 10, 2026

·

2 min read

·

Gabrielle Masson

Focus on the path, Businessman running on his own track

Rare diseases

Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug

The FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency.

June 10, 2026

·

2 min read

·

Tristan Manalac

Sorting garbage concept. Cropped photo of paper thash. Crumple paper falling to the recycling bin

Rare diseases

Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy

The discontinuation of Sanofi’s Phase 3 study for its complement inhibitor drug in chronic inflammatory demyelinating polyneuropathy delivers an ‘obviously disappointing’ blow to the broader drug class, according to William Blair.

June 10, 2026

·

2 min read

·

Tristan Manalac

Podcast

Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

Eli Lilly and obesity rival Novo Nordisk stole the show at the American Diabetes Association conference, though plenty of other companies also had data to show for their own weight loss assets; GSK strikes the biggest traditional pharma buyout of 2026; and FDA initiatives still lack clarity.

June 10, 2026

·

2 min read

·

Jef Akst